Protective Effect of Hydroxysafflor Yellow A on Inflammatory Injury in Chronic Obstructive Pulmonary Disease Rats

  • Ming JinEmail author
  • Chang-jiang Xue
  • Yu Wang
  • Fang Dong
  • Yuan-yuan Peng
  • Ya-dan Zhang
  • Bao-xia Zang
  • Li Tan
Original Article



To investigate the attenuating effect of Hydroxysafflor yellow A (HSYA) on inflammatory injury in chronic obstructive pulmonary disease (COPD).


Rats were randomly assigned to 7 groups according to body weight including normal control group, HSYA blank group (76.8 mg/kg), COPD group, COPD+HSYA (30, 48, 76.8 mg/kg) groups and COPD+dexamethasone (2 mg/kg), 10 in each group. Passive cigarette smoke and intratracheal instillation of lipopolysaccharides were used to establish a COPD model in rats. Hematoxylin and eosin staining of lung tissue sections was used, real-time polymerase chain reaction (PCR) was used to assay mRNA levels of some cytokines in lung tissues, the cytokines in bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay (ELISA), Western blot analysis was used to determine phosphorylated p38 mitogen-activated protein kinase (MAPK) levels in lung tissues, and nuclear factor-κB (NF-κB) p65 protein levels in lung tissues were detected by immunohistochemistry.


Lung alveolar septa destruction, alveolus fusion, inflammatory cell infiltration, and bronchiole exudation were observed. These pathological changes were alleviated in the COPD+HSYA group. The mRNA expression of inflammatory factors were significantly increased in lung tissues from COPD rats (all P<0.01) and were inhibited by HSYA. Levels of inflammatory cytokines in BALF of COPD rats were significantly increased (all P<0.01) which were inhibited by HSYA (all P<0.01, 48, 76.8 mg/kg). The levels of p38 MAPK phosphorylation and p65 in lung tissues of COPD rats were significantly increased (all P<0.01) and were suppressed by HSYA (all P<0.01, 48, 76.8 mg/kg).


HSYA could alleviate inflammatory cell infiltration and other pathological changes in the lungs of COPD rats. HSYA inhibited inflammatory cytokine expression, and increase phosphorylation of p38 MAPK and NF-κB p65 in the lungs of COPD rats. The protective mechanism of HSYA to inhibit COPD inflammation might be by attenuating NF-κB and p38MAPK signal transduction.


Hydroxysafflor yellow A chronic obstructive pulmonary disease inflammation p38 mitogen-activated protein kinase nuclear factor-κB 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347–365.CrossRefGoogle Scholar
  2. 2.
    Chinese Society of Respiratory Diseases, Guideline for diagnosis and management of COPD (Revised in 2007). Chin J Tuberc Respir Dis (Chin) 2007;30:8-17.Google Scholar
  3. 3.
    Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397–412.CrossRefGoogle Scholar
  4. 4.
    Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546–3556.CrossRefGoogle Scholar
  5. 5.
    Wang HL. Modern study review of Safflor Yellow. Chin J Tradit Med Sci Technol 1998;5:333–334.Google Scholar
  6. 6.
    Feng ZM, He J, Jiang JS, Chen Z, Yang YN, Zhang PC. NMR solution structure study of the representative component hydroxysafflor yellow A and other quinochalcone C-glycosides from Carthamus tinctorius. J Nat Prod 2013;76:270–274.CrossRefGoogle Scholar
  7. 7.
    Sun CY, Pei C, Zang BX, Wang L, Jin M. The ability of hydroxysafflor yellow A to attenuate lipopolysaccharideinduced pulmonary inflammatory injury in mice. Phytother Res 2010;24:1788–1795.CrossRefGoogle Scholar
  8. 8.
    Wang Y, Xue CJ, Dong F, Peng YY, Zhang YD, Jin M, et al. Hydroxysafflor yellow A attenuates small airway remodeling in a rat model of chronic obstructive pulmonary disease. Biol Pharm Bull 2014;37:1591–1598.CrossRefGoogle Scholar
  9. 9.
    Gaschler G, Bauer C, Zavitz C, Stämpfli M. Animal models of chronic obstructive pulmonary disease exacerbations, models of exacerbations in asthma and COPD. Contrib Microbiol Basel Karger 2007;14:126–141.CrossRefGoogle Scholar
  10. 10.
    Zang BX, Jin M, Li JR. Large scale preparation of pure hydroxysafflor yellow A by macroporus resin-gel column chromatography. J Cardiovasc Pulm Dis 2008,27:363–365.Google Scholar
  11. 11.
    Barbu C, Iordache M, Man MG. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol 2011;52:21–27.Google Scholar
  12. 12.
    Vernooy JHJ, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 2002;26:152–159.CrossRefGoogle Scholar
  13. 13.
    Li HM, Cui DJ, Tong X, Pang BS, Gao YB, Wang DW. Establishment of chronic obstructive pulmonary disease rat models by passive cigarette smoking and intratracheal instillation of lipopolysaccharide. Chin J Pathophysiol (Chin) 2002;18:808–812.Google Scholar
  14. 14.
    Pei CQ, Sun CY, Jin M. Mitigation of safflor yellow injection on acute lung injury of rats induced by oleic acid. Chin Tradit Herb Drugs (Chin) 2010;41:597–601.Google Scholar
  15. 15.
    Fan J, Richard DY, Malik AB. Transcriptional mechanisms of acute lung injury. Am J Lung Cell Mol Physiol 2001;281:L1037–L1050.CrossRefGoogle Scholar
  16. 16.
    Hudry-Clergeon H, Stengel D, Ninio E, Vilgrain I. Platelet-activating factor increases VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3'-kinase. FASEB J 2005;19:512–520.CrossRefGoogle Scholar
  17. 17.
    Zhang Q, Chen ZY, Wu LB, Wang SC, Zheng QS. Clinical non-feriority evaluation on the efficacy and safety of safflower yellow pigment lyophilized power & dripping solution in the treatment of patients with angina. Chin J Evid-Based Med 2005;15:276–285.Google Scholar
  18. 18.
    Wang L, Jin M, Zang BX, Wu Y. Inhibitory effect of Safflor Yellow on pulmonary fibrosis. Biol Pharm Bull 2011;34:511–516.CrossRefGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2018

Authors and Affiliations

  • Ming Jin
    • 1
    Email author
  • Chang-jiang Xue
    • 1
  • Yu Wang
    • 1
  • Fang Dong
    • 1
  • Yuan-yuan Peng
    • 1
  • Ya-dan Zhang
    • 1
  • Bao-xia Zang
    • 1
  • Li Tan
    • 1
  1. 1.Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical UniversityBeijing Institute of Heart Lung and Blood Vessel DiseasesBeijingChina

Personalised recommendations